A Study With L19TNF in Combination With Lomustine in Patients With Glioblastoma at Progression or Recurrence
← catalyst calendarSponsored by Philogen S.p.A. (industry) · PHIL.MI — their whole pipeline →.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
90estimated
Sites
9
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-05-22 | actual | When the study began enrolling |
| Primary completion | Jun 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jun 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2024-03-28 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-21 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Glioblastoma
Interventions
- Drug: L19TNF — also filed as onfekafusp alfa
- Drug: L19TNF — also filed as onfekafusp alfa
- Drug: L19TNF — also filed as onfekafusp alfa
- Drug: Lomustine
- Drug: Lomustine
Primary outcomes
what the primary-completion date above is the date OFAdverse Events
measured From the screening, throughout the study, until demonstration of confirmed disease progression, treatment begins with another anti-cancer agent or surgery, or for a minimum of 12 months
Serious Adverse Events
measured From the screening, throughout the study, until demonstration of confirmed disease progression, treatment begins with another anti-cancer agent or surgery, or for a minimum of 12 months
Unacceptable Toxicity
measured From the start of treatment up to 3 months
DILI assessment
measured From the screening, throughout the study, until demonstration of confirmed disease progression, treatment begins with another anti-cancer agent or surgery, or for a minimum of 12 months
Survival
measured From enrollment to death from any cause, for a minimum of 12 months
Permalink · PHIL.MI's whole pipeline · Catalyst calendar · Every registered study · What changed